proline and lopinavir

proline has been researched along with lopinavir in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (33.33)	24.3611
2020's	2 (66.67)	2.80

Authors

Authors	Studies
Butterton, JR; Feng, HP; Hughes, EA; Hulskotte, EG; O'Mara, E; Treitel, MA; van Zutven, MG; Wagner, JA; Xuan, F; Youngberg, SP	1
Chen, H; Huang, Y; Ju, W; Li, X; Peng, X; Rao, J; Sun, H; Tu, X; Wang, L; Wang, S; Zhang, Z; Zhu, D	1
Ahmad, B; Ain, QU; Batool, M; Choi, S; Kim, MS	1

Trials

1 trial(s) available for proline and lopinavir

Article	Year
Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 56, Issue:5 Topics: Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Darunavir; Dose-Response Relationship, Drug; Drug Interactions; Female; Hepacivirus; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Pyridines; Ritonavir; Sulfonamides; Young Adult	2013

Article

Year

Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013, Volume: 56, Issue:5

Topics: Adult; Anti-HIV Agents; Area Under Curve; Atazanavir Sulfate; Darunavir; Dose-Response Relationship, Drug; Drug Interactions; Female; Hepacivirus; HIV Protease Inhibitors; HIV-1; Humans; Lopinavir; Male; Middle Aged; Oligopeptides; Proline; Protease Inhibitors; Pyridines; Ritonavir; Sulfonamides; Young Adult

2013

Other Studies

2 other study(ies) available for proline and lopinavir

Article	Year
A comparative study on the time to achieve negative nucleic acid testing and hospital stays between danoprevir and lopinavir/ritonavir in the treatment of patients with COVID-19. Journal of medical virology, 2020, Volume: 92, Issue:11 Topics: Adolescent; Adult; Aged; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Nucleic Acid Testing; Cyclopropanes; Drug Combinations; Female; Humans; Isoindoles; Lactams, Macrocyclic; Length of Stay; Lopinavir; Male; Middle Aged; Proline; Ritonavir; Severity of Illness Index; Sulfonamides; Young Adult	2020
Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations. International journal of molecular sciences, 2021, Aug-24, Volume: 22, Issue:17 Topics: Antiviral Agents; Catalytic Domain; Coronavirus 3C Proteases; Coronavirus Protease Inhibitors; COVID-19 Drug Treatment; Humans; Lactams; Leucine; Lopinavir; Molecular Docking Simulation; Molecular Dynamics Simulation; Nitriles; Proline; Ritonavir; SARS-CoV-2	2021

Article

Year

A comparative study on the time to achieve negative nucleic acid testing and hospital stays between danoprevir and lopinavir/ritonavir in the treatment of patients with COVID-19.

Journal of medical virology, 2020, Volume: 92, Issue:11

Topics: Adolescent; Adult; Aged; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; COVID-19 Nucleic Acid Testing; Cyclopropanes; Drug Combinations; Female; Humans; Isoindoles; Lactams, Macrocyclic; Length of Stay; Lopinavir; Male; Middle Aged; Proline; Ritonavir; Severity of Illness Index; Sulfonamides; Young Adult

2020

Exploring the Binding Mechanism of PF-07321332 SARS-CoV-2 Protease Inhibitor through Molecular Dynamics and Binding Free Energy Simulations.

International journal of molecular sciences, 2021, Aug-24, Volume: 22, Issue:17

Topics: Antiviral Agents; Catalytic Domain; Coronavirus 3C Proteases; Coronavirus Protease Inhibitors; COVID-19 Drug Treatment; Humans; Lactams; Leucine; Lopinavir; Molecular Docking Simulation; Molecular Dynamics Simulation; Nitriles; Proline; Ritonavir; SARS-CoV-2

2021